Twelve of the country’s largest not-for-profit health systems ended 2018 with $3.7 billion in collective investment losses last year in the stock market downturn that erupted out of political and economic fears.

Insurance plans should be ready to take a short-term financial hit to achieve savings from biosimilars, FDA Commissioner Dr. Scott Gottlieb advised.

Inpatient psychiatric facilities must abide by outmoded and inconsistently applied regulations that pile up costs, a new industry report says.

There are alternatives for achieving Medicare for All's goals, says Editor Emeritus Merrill Goozner.

The FDA has finalized two guidances to support the development of new prescription HIV antiretroviral medications, HHS Secretary Alex Azar said.

The lawsuit against AbbVie targets Humira's patents, which protect the blockbuster drug from U.S. competition. Congress has ramped up scrutiny of the entire drug patent system.

At Scripps, board diversity has been important for the different perspectives and experiences it brings in shaping the organization’s direction. 

Financial experts say not-for-profit health systems this year are more likely to consider derivative transactions to try to lower financing costs now that tax-exempt advance refunding is off the table.

New payment programs that include both upside and downside risk seem perpetually stuck in a state of delay, researchers said.

Unlike Medicare, the VA, most Medicaid programs and most commercial insurers, UnitedHealthcare—the nation’s largest insurer—excludes urinary catheters from coverage for many commercial plans.

New payment programs that include both upside and downside risk seem perpetually stuck in a state of delay, researchers said.

Massachusetts' second-largest health insurer aims to grow its Medicare Advantage business both organically and through mergers and acquisitions, CEO Michael Carson said.